NEW YORK, June 26, 2026, 14:01 EDT
- Eli Lilly climbed 6.5% during the day, tacking on around $65.7 billion to its market cap.
- Lilly makes up 15.84% of XLV. Its move added about 1.03 points to the ETF’s 2.4% jump.
- The market reaction dwarfed Jaypirca’s sales. Traders are focused on GLP-1 access and index weight here, not only an update on one cancer drug.
- Medicare’s GLP-1 Bridge begins July 1 and will continue until Dec. 31, 2027.
Eli Lilly and Company NYSE:LLY jumped 6.5% to $1,200.98 by 1:46 p.m. EDT Friday, tacking on about $65.7 billion in market cap. Shares hovered close to the session’s high of $1,208.18. The stock was at 42.7 times earnings, with 3.6 million shares traded.
The index math told more of the story. Lilly made up 15.84% of the Health Care Select Sector SPDR Fund (NYSEARCA:XLV) as of June 25, State Street said. Based on that, Lilly’s move on Friday added about 1.03 percentage points to XLV—roughly 43% of the ETF’s 2.4% rise at one point. State Street Global Advisors
Lilly’s huge weight in XLV looms large for holders. Any big news on a drug or pricing can sway the whole U.S. healthcare sector now. The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) barely moved Friday, so the action in health care was more obvious.
Lilly shares moved up after the company said the European Medicines Agency’s CHMP recommended Jaypirca for adults with chronic lymphocytic leukemia in any line of therapy. The company said the European Commission’s decision could come in one to two months. If Jaypirca is approved, the drug’s EU label would expand. Jacob Van Naarden, Lilly Oncology’s president, called Jaypirca a “meaningful new option” for newly diagnosed patients and those who haven’t had a BTK inhibitor. Eli Lilly and Company
The stock move seemed outsized for Jaypirca’s numbers. Jaypirca brought in $165 million in Q1, which is just 0.8% of Eli Lilly’s $19.8 billion sales for the quarter. Mounjaro and Zepbound brought in $12.8 billion together. In April, Lilly boosted its 2026 revenue outlook to $82 billion to $85 billion. PR Newswire
Lilly says Medicare Part D patients who qualify can get Foundayo or Zepbound for weight management at $50 a month through the Medicare GLP-1 Bridge, starting July 1. Ilya Yuffa, a Lilly executive, said around 20 million Medicare patients may meet the clinical criteria and called the move a way to make obesity treatment “within reach” for many. The bigger investor focus is on access to obesity drugs. Eli Lilly and Company
CMS is starting the Medicare GLP-1 Bridge July 1, 2026, with the program set to run through Dec. 31, 2027. It will run outside the regular Part D payment and coverage process. The Bridge covers specific GLP-1 drugs for certain Part D beneficiaries. Centers for Medicare & Medicaid Services
Lilly gets a window for demand ahead of knowing full payer economics for 2027–2028. For investors, this sets a benchmark. Volume growth needs to make up for lower realized pricing, which Lilly pointed out in Q1.
China is the next access hurdle. Lilly Executive VP Patrik Jonsson told Reuters this week that orforglipron may reach China “anything from late 2026 to early 2027.” Reuters said GLP-1 sales through top Chinese e-commerce names Alibaba and JD.com came to about 1.4 billion yuan, or $207 million, in the first quarter, citing Jefferies. Reuters
Eli Lilly could face tougher price terms in Europe. Jonsson told Reuters the company aims for “public coverage, wherever possible,” but said most-favored-nation pricing “will play a role for all launches” as Lilly gets ready to roll out its weight-loss pills in Europe and the UK. Reuters
Wall Street targets for the stock are tighter after the recent run. Of 22 analysts tracked by Google Finance, 20 have buys and two have holds, with the average 12-month target at $1,290.79. On June 25, Leerink’s David Risinger kept his Buy and a $1,232 price target, just a bit above where shares closed Friday. Google
Lilly is set to report earnings on Aug. 5, with the call slated for 10 a.m. EDT. lilly.gcs-web.com
